Convertible noteholder treatment under restructuring plan
Company: Core Scientific
The claim, verbatim
Under the restructuring term sheet, convertible noteholders are to receive $150 million in New Secured Notes, $260 million in New Secured Convertible Notes, and $260 million in equity, plus contingent payment obligations of up to $130 million.
Source (primary)
core-scientific 8-K exhibit (d524676dex992.htm) (SEC EDGAR (8-K Ex), press_release)
View cached copy (2026-11-18)Live source ↗
Quote: “$150 million in New Secured Notes - $260 million in New Secured Convertible Notes - $260 million in Equity”
How we checked this
Checked on November 20, 2026. The cited source supports every part of this claim.
The term sheet lists this treatment for the April and August convertible notes: $150 million in New Secured Notes, $260 million in New Secured Convertible Notes, $260 million in equity, and contingent payment obligations of up to $130 million.
Confirmed in the source:
- Under the restructuring term sheet, convertible noteholders are to receive $150 million in New Secured Notes
- Convertible noteholders are to receive $260 million in New Secured Convertible Notes
- Convertible noteholders are to receive $260 million in equity
- Convertible noteholders are to receive contingent payment obligations of up to $130 million total
What we did: Read our cached copy of SEC EDGAR (8-K Ex) (https://www.sec.gov/Archives/edgar/data/1839341/000119312523266221/d524676dex992.htm) in full (18,293 characters, retrieved November 18, 2026) and checked each assertion in the claim against it.
Additional evidence
confirms core-scientific 8-K exhibit (d524676dex992.htm)
Quote: “$150 million in New Secured Notes - $260 million in New Secured Convertible Notes - $260 million in Equity”